Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus‐induced genital lesions - Concepedia

Concepedia

Publication | Open Access

Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus‐induced genital lesions

DOI Full Paper Access

19

Citations

21

References

2019

Year

M. Rijsbergen, Rianne Rijneveld, M. Todd, Gary Feiss, S.T.P. Kouwenhoven, Koen D. Quint, Dirk C.J.G. van Alewijk, Maurits N.C. de Koning, Erica S. Klaassen, Jacobus Burggraaf,

British Journal of Clinical Pharmacology

Abstract

Topical omiganan appears to be safe in patients with AGW and vulvar HSIL and reduced human papillomavirus load after 12 weeks of treatment in AGW patients.

References

	Year	Citations

Page 1